The U.S. Food and Drug Administration granted full approval to Orphalan’s Cuvrior (trientine tetrahydrochloride) for the treatment of Wilson’s disease, a rare genetic disorder. The approval announcement marks the first new treatment available for patients in over five decades.
Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.
Dr. Reddy’s Laboratories Ltd. announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration for treating Wilson’s disease.
Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.